Najat Khan, PhD, unpacks realistic timelines for AI-based drugs to make clinical impact and her priorities for Recursion as incoming CEO.

We consider a multivariate distributional recursion of sum type, as arises in the probabilistic analysis of algorithms and random trees. We prove an upper tail bound for the solution using Chernoff's ...

SALT LAKE CITY--(BUSINESS WIRE)--Recursion, a Fast Company “Most Innovative Company” and leader in the artificial intelligence for drug discovery movement, today announced it will open-source a ...